64 / 69
64
70.
Marin D, Bazeos A, Mahon FX, Eliasson L, Milojkovic D,
Bua M, et al. Adherence is the critical factor for achieving
molecular responses in patients with chronic myeloid
leukemia who achieve complete cytogenetic responses on
imatinib. J Clin Oncol 2010;28:2381-8.
71.
Ibrahim AR, Eliasson L, Apperley JF, Milojkovic D, Bua M,
Szydlo R, et al. Poor adherence is the main reason for loss
of CCyR and imatinib failure for chronic myeloid
leukemia patients on long-term therapy. Blood
2011;117:3733-6.
72.
Ganesan P, Sagar TG, Dubashi B, Rajendranath R, Kannan
K, Cyriac S, et al. Nonadherence to imatinib adversely
affects event free survival in chronic phase chronic
myeloid leukemia. Am J Hematol 2011;86:471-4.
73.
Jabbour E, Kantarjian H, O'Brien S, Shan J, Garcia-Manero
G, Wierda W, et al. Predictive factors for outcome and
response in patients treated with second-generation
tyrosine kinase inhibitors for chronic myeloid leukemia in
chronic phase after imatinib failure. Blood 2011;117:1822-7.
74.
Branford S, Rudzki Z, Walsh S, Parkinson I, Grigg A, Szer
J, et al. Detection of BCR-ABL mutations in patients with
CML treated with imatinib is virtually always
accompanied by clinical resistance, and mutations in the
ATP phosphate-binding loop (P-loop) are associated with
a poor prognosis. Blood 2003;102:276-83.
75.
Soverini S, Martinelli G, Rosti G, Bassi S, Amabile M,
Poerio A, et al. ABL mutations in late chronic phase
chronic myeloid leukemia patients with up-front
cytogenetic resistance to imatinib are associated with a
greater likelihood of progression to blast crisis and shorter
survival: a study by the GIMEMA Working Party on
Chronic Myeloid Leukemia. J Clin Oncol 2005;23:4100-9.
76.
Jabbour E, Kantarjian H, Jones D, Talpaz M, Bekele N,
O'Brien S, et al. Frequency and clinical significance of